Compare Cytokinetics Inc (CYTK) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vertiv Holdings Co — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Vertiv Holdings Co trades at $247.2 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 10.9× Cytokinetics Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vertiv Holdings Co for 39 Days on average.
| CYTK | VRT | |
|---|---|---|
Market Cap | $8.62B | $93.83B |
Volume | 2,594,626 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $87.26 | $376.23 |
52-Week Low | $54.76 | $149.83 |
Typical Hold Time | 19 Days | 39 Days |
Enterprise Value | $8.72B | $94.06B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Vertiv (VRT) trades at $246.49, down 2.63% on the day, as technical indicators show bearish momentum with the stock testing support near $242. Fundamentally, the company demonstrates strong profitability with 38% gross margins and 15% net income margins, while recent earnings have consistently beaten expectations. Revenue growth accelerated from $10.2B in 2025 to $11.5B projected for 2026, driven by AI data center demand.
The investment case balances strong analyst support (95% buy ratings with $364.94 price target) against elevated valuation multiples (P/E of 55) and recent legal scrutiny. While AI infrastructure tailwinds provide growth catalysts, the stock faces technical headwinds and needs to maintain its earnings beat streak to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
